




RealRate

PHARMACEUTICAL 2022

Larimar Therapeutics Inc
Rank 227 of 471



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Larimar Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Larimar Therapeutics Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 52% points. The greatest weakness of Larimar Therapeutics Inc is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 32% points.

The company's Economic Capital Ratio, given in the ranking table, is 298%, being 23% points above the market average of 275%.

Input Variable	Value in 1000 USD
Assets, Current	72,204
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	8,846
Liabilities, Non-Current	5,408
Other Assets	5,414
Other Compr. Net Income	-1.0
Other Expenses	0
Other Liabilities	0
Other Net Income	-171
Other Revenues	0
Property and Equipment	1,049
Research and Development	38,396
Selling, General and Administrative Expense	12,069

Output Variable	Value in 1000 USD
Assets	78,667
Liabilities	14,254
Expenses	50,465
Revenues	0
Stockholders Equity	64,413
Net Income	-50,636
Comprehensive Net Income	-50,636
BaseVar	71,779
ECR before Limited Liability	193%
Economic Capital Ratio	298%